43
Participants
Start Date
June 5, 2018
Primary Completion Date
June 30, 2023
Study Completion Date
November 18, 2025
Pembrolizumab
Given IV
Talimogene Laherparepvec
Given IL
University of South Alabama Mitchell Cancer Institute, Mobile
Vanderbilt University/Ingram Cancer Center, Nashville
Ohio State University Comprehensive Cancer Center, Columbus
University of Cincinnati Cancer Center-West Chester, West Chester
University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
Henry Ford Macomb Hospital-Clinton Township, Clinton Township
Henry Ford Cancer Institute-Downriver, Brownstown
Henry Ford Hospital, Detroit
Henry Ford West Bloomfield Hospital, West Bloomfield
Allegiance Health, Jackson
Loyola University Medical Center, Maywood
Kansas City Veterans Affairs Medical Center, Kansas City
University of Kansas Hospital-Westwood Cancer Center, Westwood
Huntsman Cancer Institute/University of Utah, Salt Lake City
CTCA at Western Regional Medical Center, Goodyear
Los Angeles General Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Keck Medical Center of USC Pasadena, Pasadena
National Cancer Institute (NCI)
NIH